Selskabets formål er at drive handel, derunder import og eksport samt agenturvirksomhed med kemiske og pharmaceutiske produkter, medicinalvarer, artikler til sådanne frembringelser.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 329.6 mio. | 10.5 mio. | 88.5 mio. | 32.5 mio. | 14 | |
CVR: 20601116
Secondary names: ERCOPHARM A/S
Compared to 409 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 41722460
CVR 39371049
CVR 39503778
CVR 40873309
CVR 31774284
The financial health of ORION PHARMA A/S appears stable, with a notable upward trend in revenue over the past few years. Revenue increased from 214.2 million DKK in 2022 to 329.6 million DKK in 2025, while profit also rose from 4.5 million DKK in 2021 to 10.5 million DKK in 2025, indicating improved profitability. However, equity has fluctuated, peaking at 51.7 million DKK in 2023 before declining to 32.5 million DKK in 2025, which may raise concerns about financial stability. Overall, the company is positioned well within the pharmaceutical wholesale industry, benefiting from growing demand for medicinal products and healthcare supplies.
AI-generated summary
companydata.dk